Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
复制标题
激素受体状态，肿瘤特征和预后：乳腺癌患者的前瞻性队列。
DOI：
10.1186/bcr1639
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Li CI
中科院分区：
文献类型：
--
作者：
Dunnwald LK;Rossing MA;Li CI
与ER和/或PR阴性疾病的女性相比，患有雌激素受体（ER）阳性和/或孕激素受体（PR）阳性肿瘤的乳腺癌患者在诊断后的死亡风险较低。然而，很少有研究通过人口统计学或临床特征评估ER/PR状态下乳腺癌特异性死亡率风险的变化。使用来自参与SEER（监测、流行病学和最终结果）计划的11个基于人群的癌症登记处的数据，1990年至2001年期间，155，175名至少30岁的主要诊断为浸润性乳腺癌的女性被纳入研究。使用考克斯比例风险模型评估了关节激素受体状态与诊断年龄、诊断年份、种族/民族、组织学肿瘤类型、分期、分级、大小和腋窝淋巴结状态等类别中乳腺癌死亡风险之间的关联。与ER+/PR+病例相比，在诊断时年龄的所有亚类中均观察到死亡风险升高，ER+/PR-病例的差异范围为1.2- 1.5倍，ER-/PR+病例的差异范围为1.5- 2.1倍，ER-/PR-病例的差异范围为2.1- 2.6倍。在按年级分层的分析中观察到更大的差异;在低级别病变的女性中，ER-/PR-患者有2.6倍的（95%置信区间[CI] 1.7至3.9）至3.1倍（95% CI 2.8至3.4）与ER+/PR+患者相比，死亡风险增加，但在高级别病变的女性中，他们的风险增加了2.1倍（95% CI 1.9至2.2）至2.3倍（95% CI 1.8至2.8）。与ER+/PR+肿瘤患者相比，ER+/PR-、ER-/PR+或ER-/PR-肿瘤患者的死亡风险更高，这在很大程度上与本研究中评估的各种人口统计学和临床肿瘤特征无关。在ER-/PR-患者中发现的较小或低级别肿瘤的相对死亡风险较高，这提出了一个问题，即辅助化疗是否可能在这一人群中发挥有益作用。
Breast cancer patients with tumors that are estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive have lower risks of mortality after their diagnosis compared to women with ER- and/or PR-negative disease. However, few studies have evaluated variations in the risks of breast cancer-specific mortality across ER/PR status by either demographic or clinical characteristics. Using data from 11 population-based cancer registries that participate in the SEER (Surveillance, Epidemiology, and End Results) program, 155,175 women at least 30 years old with a primary diagnosis of invasive breast carcinoma from 1990 to 2001 were included in the study. Associations between joint hormone receptor status and breast cancer mortality risk within categories of diagnosis age, diagnosis year, race/ethnicity, histologic tumor type, stage, grade, size, and axillary lymph node status were evaluated using the Cox proportional hazards model. Compared to ER+/PR+ cases, elevations in risk of mortality were observed across all subcategories of age at diagnosis, ranging from 1.2- to 1.5-fold differences for ER+/PR- cases, 1.5- to 2.1-fold differences for ER-/PR+ cases, and 2.1- to 2.6-fold differences for ER-/PR- cases. Greater differences were observed in analyses stratified by grade; among women with low-grade lesions, ER-/PR- patients had a 2.6-fold (95% confidence interval [CI] 1.7 to 3.9) to 3.1-fold (95% CI 2.8 to 3.4) increased risk of mortality compared to ER+/PR+ patients, but among women with high-grade lesions, they had a 2.1-fold (95% CI 1.9 to 2.2) to 2.3-fold (95% CI 1.8 to 2.8) increased risk. Compared to women with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality, which were largely independent of the various demographic and clinical tumor characteristics assessed in this study. The higher relative mortality risks identified among ER-/PR- patients with small or low-grade tumors raise the question of whether there may be a beneficial role for adjuvant chemotherapy in this population.
登录
查看更多内容
影响因子：
5.8
作者：
Cianfrocca, M;Goldstein, LJ
通讯作者：
Goldstein, LJ
影响因子：
8.8
作者：
Li, CI;Uribe, DJ;Daling, JR
通讯作者：
Daling, JR
长期随访2257种可手动乳腺癌后，类固醇受体的预后价值。
影响因子：
8.8
作者：
Pichon, M F;Broet, P;Magdelenat, H;Delarue, J C;Spyratos, F;Basuyau, J P;Saez, S;Rallet, A;Courriere, P;Millon, R;Asselain, B
通讯作者：
Asselain, B
影响因子：
120.7
作者：
Berry, DA;Cirrincione, C;Winer, EP
通讯作者：
Winer, EP
影响因子：
3.8
作者：
Osborne, CK
通讯作者：
Osborne, CK